Centre Hospitalier Universitaire de Bordeaux, Service de Médecine Physique et de Réadaptation, Unité de Médecine Orthopédique et Sportive, Bordeaux, Aquitaine, France.
Clinique du Sport de Bordeaux Mérignac, Mérignac, Nouvelle-Aquitaine, France.
Clin J Sport Med. 2022 Nov 1;32(6):567-573. doi: 10.1097/JSM.0000000000001066. Epub 2022 Sep 5.
Adductor-related groin pain (ARGP) is the most common groin injury in athletes. If conservative treatment fails, then adductor tenotomy to relieve tension can be considered. The use of botulinum toxin A (BoNT-A) has shown good results in other musculoskeletal pathologies.
Assess the effectiveness of BoNT-A injections in ARGP in cases where usual treatment has failed.
Retrospective cohort study.
Orthopedic Medicine and Rehabilitation Unit, University of Bordeaux.
Fifty patients treated by BoNT-A injection in ARGP after failure of medical and/or surgical treatment were included in this study.
One or several adductor muscles were injected with BoNT-A, according to clinical evaluation using ultrasound and electrical stimulation guidance. Patients were followed up at 1, 3, 6, and 12 months.
The primary assessment criterion was the improvement of Hip and Groin Outcome Score subscales at day 30. Secondary outcomes included pain intensity and impact on sport, work, and quality of life (QoL), the Blazina scale, and side effects.
All the first 50 injected patients (45 male and 5 female patients) were included. A significant improvement was noted regarding the majority of Hip and Groin Outcome Score subscales at day 30 ( P < 0.05). Pain intensity and its impacts were both significantly reduced ( P < 0.001): less sport and professional disability and lower impact on QoL. Severity of symptoms assessed by the Blazina scale was significantly reduced ( P < 0.001). The improvements remained significant until 1-year postinjection.
BoNT-A is promising as a new treatment for ARGP but should be fully assessed in a randomized controlled trial.
内收肌相关腹股沟疼痛（ARGP）是运动员中最常见的腹股沟损伤。如果保守治疗失败，则可以考虑行内收肌切开术以缓解张力。肉毒毒素 A（BoNT-A）的应用已在其他肌肉骨骼病理学中显示出良好的效果。
评估 BoNT-A 注射治疗常规治疗失败后的 ARGP 的疗效。
回顾性队列研究。
波尔多大学骨科医学与康复科。
本研究纳入了 50 例经药物和/或手术治疗失败后接受 BoNT-A 注射治疗 ARGP 的患者。
根据超声和电刺激引导的临床评估，对 1 或多个内收肌进行 BoNT-A 注射。患者在 1、3、6 和 12 个月时进行随访。
主要评估标准为 30 天时髋关节和腹股沟结局评分亚量表的改善。次要结局指标包括疼痛强度和对运动、工作和生活质量（QoL）的影响、Blazina 量表以及副作用。
所有最初的 50 例接受注射的患者（45 例男性和 5 例女性）均被纳入研究。在 30 天时，大多数髋关节和腹股沟结局评分亚量表均有显著改善（P<0.05）。疼痛强度及其影响均显著降低（P<0.001）：运动和职业障碍减少，对 QoL 的影响降低。Blazina 量表评估的症状严重程度显著降低（P<0.001）。注射后 1 年时，改善仍具有统计学意义。
BoNT-A 有望成为 ARGP 的一种新治疗方法，但仍需在随机对照试验中进行全面评估。
